1 s that are required for the development of a lupus-like syndrome.

2 reat Graves' disease, occasionally induces a lupus-like syndrome.

3 f a stimulatory graft-vs-host disease with a lupus-like syndrome.

4 ular disease, thrombocytopenia, and systemic lupus-like syndrome.

5 s the first evidence that the induction of a lupus-like syndrome by pristane is not restricted to BAL

6                    BALB/c ByJ mice develop a lupus-like syndrome characterized by anti-nRNP/Sm and Su

7 ainamide and numerous other medications is a lupus-like syndrome characterized by autoantibodies dire

8 as (lpr) or Fas ligand (gld) cause a limited lupus-like syndrome in B6 mice by interfering with the d

9                           Pristane induces a lupus-like syndrome in nonautoimmune mice characterized

10 the development of anti-dsDNA antibodies and lupus-like syndrome in patients undergoing anti-TNF ther

11 tion of Tlr7 and 16 other genes, exacerbates lupus-like syndromes in several mouse strains.

12 function might contribute to the etiology of lupus-like syndromes in the context of an autoimmune-pro

13 nti-nRNP/Sm (+) sera from BALB/c mice with a lupus-like syndrome induced by pristane recognized Ul-C.

14 tment of NZB/WF1 mice, which develop a fatal lupus-like syndrome, inhibited NF-kappaB2 processing and

15                 As mice lacking Ro develop a lupus-like syndrome, Ro may be important for preventing

16 raperitoneal injection of pristane induces a lupus-like syndrome whose pathogenesis implicates the se

17 subjects with trisomy of chromosome 9p had a lupus-like syndrome with joint manifestations and antinu

18 d be aware of the propensity of PTU to cause lupus-like syndromes with renal involvement.